Dianthus Therapeutics Q4 2023 Earnings Report $19.99 +0.12 (+0.60%) As of 04:00 PM Eastern Earnings HistoryForecast Dianthus Therapeutics EPS ResultsActual EPS-$0.71Consensus EPS -$1.11Beat/MissBeat by +$0.40One Year Ago EPSN/ADianthus Therapeutics Revenue ResultsActual Revenue$0.46 millionExpected Revenue$0.73 millionBeat/MissMissed by -$270.00 thousandYoY Revenue GrowthN/ADianthus Therapeutics Announcement DetailsQuarterQ4 2023Date3/21/2024TimeN/AConference Call ResourcesPress ReleaseDNTH Earnings HistoryPowered by Remove Ads Dianthus Therapeutics Earnings HeadlinesDianthus Therapeutics (DNTH) Expected to Announce Quarterly Earnings on ThursdayMarch 18, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for DNTH FY2025 EarningsMarch 18, 2025 | americanbankingnews.comTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 28, 2025 | Porter & Company (Ad)Stifel maintains Buy rating on Dianthus Therapeutics stockMarch 14, 2025 | uk.investing.comDianthus Therapeutics shares fall as Q4 results miss expectationsMarch 14, 2025 | investing.comWe're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn RateMarch 13, 2025 | finance.yahoo.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
